ESMO Congress 2025: Registration
Registration is now open
Related Articles
RFK Jr. Nomination Advances to Senate Floor
The Senate Finance Committee voted today in favor of Robert F. Kennedy (RFK) Jr.’s nomination for Secretary of the Department of Health and Human Services,…
Genetic and clinical spectrum of SAMD9 and SAMD9L syndromes: from variant interpretation to patient management
Sterile alpha motif domain–containing protein 9 (SAMD9) and SAMD9-like (SAMD9L) syndromes are relatively new leukemia predisposition syndromes caused by ge
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma
PURPOSEWe designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3ζ and 4-1BB/CD3ζ CARs.…
Integrative Oncology Approaches to Managing Gastrointestinal Cancer
Options like acupuncture or cannabis use may be viable to help manage symptoms related to gastrointestinal cancer treatment.
High-risk ER+ Breast Cancers Genomically Resemble HER2+ Tumors
Main Finding: HER2+ breast tumors and high-risk ER+ breast tumors share genomic features that reflect similar mechanisms of tumor evolution.Concept: The genomic architecture of breast…
Poor Indoor Air Quality Linked to Cancer & Other Issues : Oncology Times
An abstract is unavailable.
Cancer Patients Report Positive and Negative Experiences When Sharing Information With Providers
“Provider prioritization of relationship-building alongside explanations could foster trust and facilitate open information exchange, supporting informed decisions,” researchers wrote.
LAURA Study Part 2: Radiation Oncology Perspective | IASLC
This episode of Lung Cancer Considered covers the recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC, based on the LAURA trial, whi …
FDA Considers BLA for Pertuzumab Biosimilar HLX11 in Breast Cancer
FDA reviews biologics license application for HLX11, a biosimilar to pertuzumab, for HER2-positive breast cancer.
Registration
Register for the AACR Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois.
